ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
BrainsWay Ltd. (BWAY) stock declined over -4.61%, trading at $7.86 on NASDAQ, down from the previous close of $8.24. The stock opened at $8.61, fluctuating between $7.84 and $8.39 in the recent session.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Employees | 134 |
Beta | 0.16 |
Sales or Revenue | $31.79M |
5Y Sales Change% | -0.027% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Devices |